Verastem Inc (VSTM)
10.90
+0.54
(+5.21%)
USD |
NASDAQ |
May 03, 16:00
10.57
-0.33
(-3.03%)
After-Hours: 20:00
Verastem Research and Development Expense (Annual): 61.36M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 61.36M |
| December 31, 2022 | 50.56M |
| December 31, 2021 | 39.35M |
| December 31, 2020 | 41.38M |
| December 31, 2019 | 45.78M |
| December 31, 2018 | 43.65M |
| December 31, 2017 | 46.42M |
| Date | Value |
|---|---|
| December 31, 2016 | 19.78M |
| December 31, 2015 | 40.56M |
| December 31, 2014 | 35.45M |
| December 31, 2013 | 25.93M |
| December 31, 2012 | 21.71M |
| December 31, 2011 | 9.883M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
39.35M
Minimum
2021
61.36M
Maximum
2023
47.68M
Average
45.78M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Johnson & Johnson | 15.08B |
| Geron Corp | 125.05M |
| Altimmune Inc | 65.80M |
| Oragenics Inc | 15.49M |
| Actinium Pharmaceuticals Inc | 38.67M |